Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution (RESISTANCE)

11 de mayo de 2026 actualizado por: Centre Hospitalier Universitaire de Nice

Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution: a Pilot Study - RESISTANCE

Worldwide, cerebrovascular accidents (also known as strokes) are the leading cause of acquired disability, the second-leading cause of dementia (after Alzheimer's disease) and the second-leading cause of death (but the leading cause of death among women). A mechanical thrombectomy (MT) allows the recanalization of the occluded cerebral artery during an acute ischemic stroke, by removing the blood clot with a mechanical device inserted endovascularly under image guidance. MTs are the optimal treatment for a large number of patients presenting an occlusion in an anterior artery (the internal carotid artery and the proximal segment of the middle cerebral artery). Reperfusion is considered satisfactory if the mTICI score at the end of the procedure is of mTICI 2c or mTICI 3. Despite these scores having been obtained by 71% of patients during the randomized trials, showing the superiority of MT over intravenous thrombolysis, only 27% of these patients were free of neurological deficits at 3 months . Therefore, there is a discrepancy between the high rate of macroscopic recanalization and clinical results. One hypothesis to explain this discrepancy is that despite high quality macroscopic recanalization, reperfusion of the cerebral microcirculation remains insufficient: macroscopic recanalization is not equivalent to microscopic reperfusion. This discrepancy also exists in cardiology: despite a high rate of coronary artery recanalization when patients with an ST- segment elevation myocardial infarction are in emergency care, half of these patients later exhibit coronary microvascular dysfunction. The absence of reperfusion is associated with an increased risk of cardiovascular death, recurring myocardial infarctions, cardiogenic shock and heart failure one year after the coronary recanalization for an ST-segment elevation myocardial infarction. It has been shown that continuous intracoronary thermodilution can be used to quantify coronary blood flow and the absolute value of microcirculatory resistance (in Wood units). There are not currently any tools that can quantify cerebral microcirculation immediately after an MT.

The aim of this study is to evaluate the feasibility and safety of using a pressure/temperature sensing guidewire to measure cerebral microcirculatory resistance using thermodilution in patients with a score of mTICI 2c or 3 after MT for the management of acute ischemic stroke in the anterior circulation.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

15

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yves CHAU, MD
  • Número de teléfono: +33 4 92 03 35 90
  • Correo electrónico: chau.hd@chu-nice.fr

Ubicaciones de estudio

    • Alpes-maritimes
      • Nice, Alpes-maritimes, Francia, 06000
        • Reclutamiento
        • Chu De Nice
        • Contacto:
          • Yves CHAU, PH
          • Número de teléfono: +33 4 92 03 35 90
          • Correo electrónico: chau.hd@chu-nice.fr

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Men or women aged 18 to 80
  • Social Security beneficiaries
  • Obtained signed consent to participate in the study
  • TICI 2c or TICI 3 score after mechanical thrombectomy
  • Patients hospitalized for ischemic stroke due to middle cerebral artery thrombosis

Exclusion Criteria:

  • Spasm of an artery without significant stenosis
  • Vessel diameter less than 1 mm
  • Severe visceral failure
  • Local infection
  • Minors
  • Adults protected by law
  • Patients deprived of their liberty
  • Subjects who are uncooperative or unable to meet the requirements of the protocol
  • Subjects participating in another clinical trial or in a period of exclusion from a previous clinical trial
  • Pregnant women

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Viabilidad del dispositivo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: fully recanalization

The measurements will be taken as follows: once satisfactory recanalization has been achieved (mTICI 2c or 3), the suction catheter will be placed at the origin of the M1 segment. Through this catheter, the pressure/temperature measurement microguide will be placed at the distal part of M1. The microcatheter will be placed on the microguide, with its tip positioned at the outlet of the aspiration catheter.

A pressure sensor will be connected to the aspiration catheter. The microcatheter will be connected to the saline injector programmed to inject saline. The microguide is replaced in the microcatheter 165 seconds after the start of the injection. The trace of the variation in parameters will be recorded on the Coroventis station. A control injection will be performed after removal of the microcatheter and microguide from the suction catheter to ensure that there are no complications due to the measurement.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The primary objective is to assess the feasibility of measuring cerebral blood flow and cerebral microcirculatory resistance using thermodilution with the rayflow microcatheter and pressurewire guide.
Periodo de tiempo: Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
The primary evaluation criterion is the proportion of patients for whom measurements of cerebral blood flow and cerebral microcirculatory resistance using thermodilution were possible.
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To assess the safety of using thermodilution to measure cerebral blood flow and cerebral microcirculatory resistance
Periodo de tiempo: Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
The safety of the procedure will be evaluated by counting the number of deaths, perforations and dissections associated with the use of the guidewire and/or the microcatheter and/or the injection of physiological serum.
Immediately after the measurement of cerebral blood flow and cerebral microcirculatory resistance using thermodilution done with the pressure temperature guidewire
To describe the clinical evolution of patients
Periodo de tiempo: DAY 90
Complications will be reported according to the recommendations of the Cardiovascular and Interventional Radiological Society of Europe
DAY 90
Determine the threshold value of the cerebral microcirculation resistance index that allows the definition of an optimal sensitivity/specificity pair for the prognosis of neurological progression (favorable or not).
Periodo de tiempo: day 90
The value of the cerebral microcirculation resistance index for distinguishing between patients who will have a favorable neurological outcome (mRS ≤ 2) and those who will have an unfavorable outcome (mRS > 2) will be calculated from the ROC curve generated by the data collected.
day 90
Measure the additional radiation dose received by patient
Periodo de tiempo: day 1
The increase in the additional dose will be compared to that corresponding to the patient's usual treatment.
day 1

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de abril de 2026

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

6 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

27 de abril de 2026

Publicado por primera vez (Actual)

5 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir